Trial reportAIDS (London, England)2009
Interruption of antiretroviral therapy is associated with increased plasma cystatin C.
Trial report in AIDS (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 51 citations in OpenAlex.
- Reductions in Plasma Cystatin C After Initiation of Antiretroviral Therapy Are Associated With Reductions in Inflammation: ACTG A5224s.Journal of acquired immune deficiency syndromes (1999) · 2015Trial
- Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals.HIV medicine · 2014Trial
- Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial.AIDS (London, England) · 2011Trial
- Cross-Sectional and Longitudinal Performance of Creatinine- and Cystatin C-Based Estimating Equations Relative to Exogenously Measured Glomerular Filtration Rate in HIV-Positive and HIV-Negative Persons.Journal of acquired immune deficiency syndromes (1999) · 2020Article
- Serum Cystatin C and Coronavirus Disease 2019: A Potential Inflammatory Biomarker in Predicting Critical Illness and Mortality for Adult Patients.Mediators of inflammation · 2020Article
- Urinary biomarkers of kidney diseases in HIV-infected children.Proteomics. Clinical applications · 2015Review
- Article
- Risk factors for ESRD in HIV-infected individuals: traditional and HIV-related factors.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2012Article
- Review
- Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Expert opinion on pharmacotherapy · 2011Review
- Analysis of biomarker data: logs, odds ratios, and receiver operating characteristic curves.Current opinion in HIV and AIDS · 2010Review
- Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2010Article
- Recent developments in HIV-related kidney disease.HIV therapy · 2010Article
- Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.The Journal of infectious diseases · 2010Article
- The treatment of HIV-associated nephropathy.Advances in chronic kidney disease · 2010Review
- Screening for chronic kidney disease in HIV-infected patients.Advances in chronic kidney disease · 2010Review
- HIV and the Kidney.Current infectious disease reports · 2009Article
- Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects.The Journal of infectious diseases · 2009Article
- HIV viremia and changes in kidney function.AIDS (London, England) · 2009Article
- Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy.F1000 medicine reports · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 2 countries.
Funding
Abstract
backgroundCystatin C has been proposed as an alternative marker of renal function. We sought to determine whether participants randomized to episodic use of antiretroviral therapy guided by CD4 cell count (drug conservation) had altered cystatin C levels compared with those randomized to continuous antiretroviral therapy (viral suppression) in the Strategies for Management of Antiretroviral Therapy trial, and to identify factors associated with increased cystatin C.
methodsCystatin C was measured in plasma collected at randomization, 1, 2, 4, 8 and 12 months after randomization in a random sample of 249 and 250 participants in the drug conservation and viral suppression groups, respectively. Logistic regression was used to model the odds of at least 0.15 mg/dl increase in cystatin C (1 SD) in the first month after randomization, adjusting for demographic and clinical characteristics.
resultsAt randomization, mean (SD) cystatin C level was 0.99 (0.26 mg/dl) and 1.01 (0.28 mg/dl) in the drug conservation and viral suppression arms, respectively (P = 0.29). In the first month after randomization, 21.8 and 10.6% had at least 0.15 mg/dl increase in cystatin C in the drug conservation and viral suppression arms, respectively (P = 0.0008). The difference in cystatin C between the treatment arms was maintained through 1 year after randomization. After adjustment, participants in the viral suppression arm had significantly reduced odds of at least 0.15 mg/dl increase in cystatin C in the first month (odds ratio 0.42; 95% confidence interval 0.23-0.74, P = 0.0023).
conclusionThese results demonstrate that interruption of antiretroviral therapy is associated with an increase in cystatin C, which may reflect worsened renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.